Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.57 |
| ▸ | TUBB | P07437 | 2/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8016 | 1.00 | NPSR1 (0.61) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL38655453 | 1.00 | NPSR1 (0.61) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL28923858 | 0.93 | NPSR1 (0.54) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL28165914 | 0.90 | NPSR1 (0.51) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| Podofilox SCHEMBL29363143 | 0.89 | LMNA (0.77) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| Podofilox SCHEMBL27708556 | 0.89 | LMNA (0.77) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL20977542 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| Ethyl Picropodophyllate SCHEMBL27895488 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL12964076 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 | |
| SCHEMBL9131949 | 0.88 | NPSR1 (0.57) | NPSR1POLBLMNACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118451106-A | Combination therapy of Claudin 18.2 antagonists and PD-1/PD-L1 axis inhibitors | 苏州创胜医药集团有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117015387-A | Attenuated cancer cells and methods relating thereto | 加利福尼亚大学董事会 | 2023-11-07 | — | — | CN | claimed |
| CN-116829192-A | Large pinocytosis selective monomer-drug conjugates | 纽约大学 | 2023-09-29 | — | — | CN | claimed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116368384-A | Compounds, targets and pathways for macrophage modulation | 麻省理工学院 | 2023-06-30 | — | — | CN | claimed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-116507617-B | 1- (2- (4-Cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxypyrrolidine-2-carboxamide derivatives as VHL inhibitors | 基因泰克公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-122029171-A | Small molecule inhibitors of KRAS proteins | 默沙东有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122028918-A | TRIM7 inhibitors and uses thereof | 沙塔克实验室有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260108512-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-120041380-A | Without systemic immunosuppression allograft tolerance | 西奈卫生系统公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2022169997-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022169998-A1 | AMIDES AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022155587-A2 | METHODS FOR DETECTING utDNA | WASHINGTON UNIVERSITY (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-4025251-A1 | METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T-CELL IMMUNOTHERAPY | PACT Pharma, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022076523-A1 | METHODS AND COMPOSITIONS FOR IMAGING AND TREATING CANCER | WASHINGTON UNIVERSITY (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108512-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | NR5A1, NR3C1, NR1H2 | NPSR1 209/4885POLB 2686/4885LMNA 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.